TICKERNERD
Menu
ARTLARTLHealthcare · Biotechnology

ARTL Stock Forecast: Artelo Biosciences, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$3.11

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 12 Oct 2026 — in the weakest quartile.

Market cap
$1.8M
Ticker Nerd rank
17 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$2.5M
Net income−$2.4M
Free cash flow−$5.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

ARTL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Artelo Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Volatility
53
Issuance
52
Growth
42
Momentum
30
Revisions
25
Accruals
18
Quality
13
Value
5

Size (99): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARTL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARTL, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2025Maxim GroupDowngradeHold—
8 Sept 2025D. Boral CapitalDowngradeHold—
26 Aug 2025D. Boral CapitalMaintainsBuy—
18 Aug 2025D. Boral CapitalMaintainsBuy—
6 Aug 2025D. Boral CapitalMaintainsBuy—
4 Aug 2025D. Boral CapitalMaintainsBuy—
8 July 2025D. Boral CapitalUpgradeBuy—
11 June 2025D. Boral CapitalDowngradeHold—
6 June 2025D. Boral CapitalMaintainsBuy—
28 Apr 2025D. Boral CapitalMaintainsBuy—
2 Apr 2025D. Boral CapitalMaintainsBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025D. Boral CapitalMaintainsBuy—
27 Feb 2025D. Boral CapitalMaintainsBuy—
14 Jan 2025D. Boral CapitalMaintainsBuy—
9 Dec 2024D. Boral CapitalMaintainsBuy—
9 Dec 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy$5.00
1 Oct 2024EF HuttonInitiatesBuy$6.00
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARTL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ARTL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Artelo Biosciences, Inc. (ARTL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 87% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−705.7%

Higher than 2% of US stocks

Return on assets
−127.9%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Artelo Biosciences, Inc. (ARTL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Artelo Biosciences, Inc. has a market value of $1.8M and an enterprise value of −$2.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$12.6M.

  • Shares outstanding: 3.5M.

  • Trailing P/E: −0.1×; forward P/E: −3.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Artelo Biosciences, Inc. employs 7 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

ARTL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARTLArtelo Biosciences, Inc.$1.8M
17
LABTLakewood-Amedex Biotherapeutics, Inc.$1.7M
21
OGENOragenics, Inc.$1.9M
10
HELPHelus Pharma, Inc.$1.5M
—
CRISCuris, Inc.$1.3M
37
GNPXGenprex, Inc.$2.2M
10
MLECMoolec Science SA$1.3M
4

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Artelo Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARTL news & analysis

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

GlobeNewsWire · 7 Oct 2026positive

Artelo Biosciences was selected to make its first company presentation at BIO-Europe 2026. The presentation will feature results from the first clinical study of ART26.12 and discuss the potential of FABP5 inhibition across multiple indications.

Why it matters — The presentation will share clinical results and provide an update on the potential scope of Artelo’s FABP5 inhibitor platform.

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

GlobeNewsWire · 23 Sept 2026positive

Artelo Biosciences filed a new provisional patent application covering ART27.13 for obesity, both as a monotherapy and in combination with GLP-1 receptor agonists, following unexpected nonclinical findings. In obese mice over four weeks, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide.

Why it matters — An ARTL watcher would care because this patent filing could protect and expand ART27.13's intellectual property position in the high-growth obesity treatment space, particularly in combination with GLP-1 receptor agonists.

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

GlobeNewsWire · 16 Sept 2026positive

Artelo Biosciences announced that its once-daily, oral candidate ART27.13 achieved weight loss comparable to semaglutide as a monotherapy and doubled weight loss when combined with semaglutide in a nonclinical model of obesity. In obese mice, ART27.13 reduced body weight by approximately 20%, matching the weight loss seen with semaglutide.

Why it matters — This data highlights ART27.13's potential in the obesity space, including as an oral option and as an add-on to existing GLP-1 therapies, which could matter for ARTL's pipeline prospects.

Artelo Biosciences Announces Reverse Stock Split

GlobeNewsWire · 27 Aug 2026neutral

Artelo Biosciences announced a reverse stock split, with shares expected to begin trading on a split-adjusted basis on August 31, 2026.

Why it matters — A reverse stock split changes the company's share structure and trading price, which ARTL watchers will need to account for in their holdings and valuation.

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

GlobeNewsWire · 20 Aug 2026positive

Artelo Biosciences announced that the Japanese Patent Office issued a notification of allowance with a Decision to Grant for its patent application covering the intended commercial formulation of ART27.13, the company's peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.

Why it matters — The granted Japanese patent helps protect the commercial formulation of ART27.13, a key pipeline asset, within an important territory.

FAQ

Frequently asked questions about ARTL stock

Is ARTL stock a buy right now?

Of the 1 analysts covering Artelo Biosciences, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Artelo Biosciences, Inc. 17 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARTL?

As at 12 Oct 2026, Artelo Biosciences, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the ARTL stock forecast for 2030?

No analyst covering Artelo Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARTL are extrapolating price history, which says nothing about the business.

What does Artelo Biosciences, Inc. do?

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways.

What is the latest news on ARTL?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform". Artelo Biosciences was selected to make its first company presentation at BIO-Europe 2026. The presentation will feature results from the first clinical study of ART26.12 and discuss the potential of FABP5 inhibition across multiple indications.

Company

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways. Artelo Biosciences concentrates on treatments for conditions with significant unmet medical needs, including cancer-related anorexia, pain, inflammation, anxiety, dermatologic disorders, and other serious diseases. Its current pipeline includes product candidates such as ART27.13, ART12.11, and ART26.12, which are being developed across multiple therapeutic areas with an emphasis on endocannabinoid and fatty acid binding protein biology. The company’s work centers on advancing novel small-molecule and cannabinoid-based approaches aimed at improving care in oncology, neurology, and related fields. Artelo Biosciences is headquartered in Solana Beach, California, and operates as a research-driven company within the broader pharmaceutical market.

CEO Mr. Gregory D. Gorgas M.B.A. · 7 employees · United States · https://artelobio.com